CA-ESRI
24.9.2020 15:54:13 CEST | Business Wire | Press release
Esri , the global leader in location intelligence, today announced a joint initiative with AfroChampions , a Pan-African nonprofit that aims to promote policies that foster private-public collaboration for Africa's economic transformation. The goal of the initiative is to engage leaders in business, governments, the African Union, and other regional economic communities through dialogue and potential partnership building in applying geospatial technology and solutions.
This new partnership with AfroChampions seeks to contribute to sustainable economic development in Africa and promote the benefits of a shared geospatial infrastructure throughout the continent. As a majority of Africans still live in rural areas, geographic information system (GIS) technology can create new opportunities for growth, especially in critical fields such as health and telemedicine, land management, agriculture, and mobility.
The powerful mapping and data analytics that GIS provides forms a foundation for some of the most successful economic strategies that nations pursue today. This initiative will offer African governments and other organizations streamlined access to Esri's world-leading GIS technology and expertise, in addition to a broad network of regional partners.
"Given the impact of the COVID-19 pandemic and related crises, African leaders must fast-track the African Continental Free Trade Area [AfCFTA], which is our own recovery plan," said Dr. Edem Adzogenu, executive director of AfroChampions. "However, we need technologies, such as geospatial solutions, to operationalize the AfCFTA."
Over the long term, Esri's solutions will advance projects retained as part of AfroChampions Trillion Dollar Investment Framework, a 360-degree road map officially endorsed by the African Union and in which core enablers of the AfCFTA are transportation and connectivity; the removal of nontariff barriers; low-cost power; and enhanced value and industrialization in a modernized digital economy.
"At a time of economic uncertainty, we consider it part of our company's mission to coordinate and collaborate with partners like AfroChampions for initiatives that promote sustainable global development," said Sohail Elabd, general manager of Esri Middle East and Africa. "With the help of a network of action-oriented business and political leaders spreading across the entire continent, these initiatives can be instrumental in advancing the use of geospatial solutions for the public good around the world, from healthcare coverage to infrastructure support."
This partnership is part of Esri's ongoing commitment to its users and the broader geospatial community across Africa. It is closely aligned with key continental initiatives such as AfCFTA; the African Development Bank Strategy for 2013–2022; the United Nations 2030 Agenda for Sustainable Development; and the African Union Agenda 2063, which emphasizes the need for global Geospatial Information for Sustainable Development (GI4SD) management.
"Esri's support is timely," continued Adzogenu. "It can help us in many practical ways, like compiling data, identifying best practices that can be replicated from one country to another, defining the right locations for strategic infrastructure projects, or launching cross-border renewable projects."
Africa Geoportal , the continent's existing geospatial community platform built by Esri, will support the AfroChampions' virtual festival Boma of Africa as well as other ongoing community outreach activities.
To learn more about how Esri is partnering with Middle Eastern and African communities to empower them with location-based sustainable solutions to global challenges, visit esri.com/en-us/about/about-esri/mea .
About AfroChampions
The AfroChampions Initiative is a public-private partnership designed to galvanize African resources and institutions to drive Africa's economic integration and transformation. As a consequence, AfroChampions supports the emergence and success of African economic champions, which have a critical role in integrating African markets and accelerating the transformation of the continent and its global competitiveness. AfroChampions is headquartered in Accra, Ghana, and works with regional and global partners and governments, with the support of other corporate and institutional partners. AfroChampions has defined four pillars of activity, all aimed at supporting Africa's economic integration. These are
- Policy advocacy: Policy-shaping and advocacy on African integration and inclusive development, with a specific focus on advancing the African Continental Free Trade area, expected to create the largest single market globally in 2021.
- Mobilizing champions for impact: Building networks and partnerships of African private and public sector champions to collaborate on African transformation projects and initiatives.
- Facilitating investments: Driving investment in game-changing projects on the continent that accelerate integration and transformation.
- Building future champions: Building and promoting the next generation of African champion institutions, innovators, and leaders.
Learn more at www.afrochampions.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969, Esri software is deployed in more than 350,000 organizations including 90 of the Fortune 100 companies, all 50 state governments, more than half of all counties (large and small), and 87 of the Forbes Top 100 Colleges in the U.S., as well as all 15 Executive Departments of the U.S. Government and dozens of independent agencies. With its pioneering commitment to geospatial information technology, Esri engineers the most advanced solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2020 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005627/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
